PARP1 inhibition elicits immune responses against non-small cell lung cancer

High levels of intracellular poly(ADP-ribose) (PAR) resulting from an elevated activity of PAR polymerase-1 (PARP1) correlate with poor infiltration of non-small cell lung cancers by cytotoxic T lymphocytes and dismal patient prognosis. Preclinical experimentation now demonstrates that PARP1 inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Juncheng, Pan, Lafarge, Antoine, Kroemer, Guido, Castedo, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Author’s View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377245/
https://www.ncbi.nlm.nih.gov/pubmed/35979387
http://dx.doi.org/10.1080/2162402X.2022.2111915
_version_ 1784768300089081856
author Juncheng, Pan
Lafarge, Antoine
Kroemer, Guido
Castedo, Maria
author_facet Juncheng, Pan
Lafarge, Antoine
Kroemer, Guido
Castedo, Maria
author_sort Juncheng, Pan
collection PubMed
description High levels of intracellular poly(ADP-ribose) (PAR) resulting from an elevated activity of PAR polymerase-1 (PARP1) correlate with poor infiltration of non-small cell lung cancers by cytotoxic T lymphocytes and dismal patient prognosis. Preclinical experimentation now demonstrates that PARP1 inhibition in cancer cells mediates strong immunostimulatory effects.
format Online
Article
Text
id pubmed-9377245
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-93772452022-08-16 PARP1 inhibition elicits immune responses against non-small cell lung cancer Juncheng, Pan Lafarge, Antoine Kroemer, Guido Castedo, Maria Oncoimmunology Author’s View High levels of intracellular poly(ADP-ribose) (PAR) resulting from an elevated activity of PAR polymerase-1 (PARP1) correlate with poor infiltration of non-small cell lung cancers by cytotoxic T lymphocytes and dismal patient prognosis. Preclinical experimentation now demonstrates that PARP1 inhibition in cancer cells mediates strong immunostimulatory effects. Taylor & Francis 2022-08-11 /pmc/articles/PMC9377245/ /pubmed/35979387 http://dx.doi.org/10.1080/2162402X.2022.2111915 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Author’s View
Juncheng, Pan
Lafarge, Antoine
Kroemer, Guido
Castedo, Maria
PARP1 inhibition elicits immune responses against non-small cell lung cancer
title PARP1 inhibition elicits immune responses against non-small cell lung cancer
title_full PARP1 inhibition elicits immune responses against non-small cell lung cancer
title_fullStr PARP1 inhibition elicits immune responses against non-small cell lung cancer
title_full_unstemmed PARP1 inhibition elicits immune responses against non-small cell lung cancer
title_short PARP1 inhibition elicits immune responses against non-small cell lung cancer
title_sort parp1 inhibition elicits immune responses against non-small cell lung cancer
topic Author’s View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377245/
https://www.ncbi.nlm.nih.gov/pubmed/35979387
http://dx.doi.org/10.1080/2162402X.2022.2111915
work_keys_str_mv AT junchengpan parp1inhibitionelicitsimmuneresponsesagainstnonsmallcelllungcancer
AT lafargeantoine parp1inhibitionelicitsimmuneresponsesagainstnonsmallcelllungcancer
AT kroemerguido parp1inhibitionelicitsimmuneresponsesagainstnonsmallcelllungcancer
AT castedomaria parp1inhibitionelicitsimmuneresponsesagainstnonsmallcelllungcancer

Ejemplares similares